Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE).
method
Treament |
Trials |
|
|
clinical deterioration | clinical improvement | deaths | PCR-negative conversion |
favipiravir | 6 | - | 0.60 [0.16; 2.26], 2 RCTs, I2=17% inconclusive result | 1.12 [0.02; 62.74], 1 RCT, I2=0% inconclusive result | 0.98 [0.21; 4.57], 2 RCTs, I2=32% inconclusive result | |
Renin-angiotensin-system-acting agents | 6 | OBS 0.73 [0.24; 2.24], 2 studies, I2=63% inconclusive result | - | OBS 0.59 [0.38; 0.92], 4 studies, I2=0% very low degree of certainty | - | |
chloroquine and derivatives | 3 | - | - | 0.66 [0.01; 35.52], 1 RCT, I2=0% inconclusive result | OBS 16.33 [2.80; 95.27], 1 study, I2=0% low degree of certainty | |
baloxavir marboxil | 1 | - | - | - | - | |
hydroxychloroquine plus macrolides | 1 | - | - | OBS 1.14 [0.56; 2.32], 1 study, I2=0% inconclusive result | - | |
remdesivir | 1 | - | 1.32 [1.12; 1.55], 1 RCT, I2=0% moderate degree of certainty | 0.70 [0.47; 1.04], 1 RCT, I2=0% inconclusive result | - | |
umifenovir (arbidol) | 1 | - | - | - | - | |
ASC09/ritonavir | 0 | - | - | - | - | |
azithromycin | 0 | - | - | - | - | |
azvudine | 0 | - | - | - | - | |
carrimycin | 0 | - | - | - | - | |
danoprevir / ritonavir | 0 | - | - | - | - | |
darunavir cobicistat | 0 | - | - | - | - | |
darunavir/cobicistat plus chloroquine | 0 | - | - | - | - | |
doxycycline | 0 | - | - | - | - | |
fluvoxamine | 0 | - | - | - | - | |
ivermectin | 0 | - | - | - | - | |
leronlimab | 0 | - | - | - | - | |
lopinavir / ritonavir plus ribavirin | 0 | - | - | - | - | |
lopinavir/ritonavir | 0 | - | - | - | - | |
lopinavir/ritonavir plus chloroquine | 0 | - | - | - | - | |
lopinavir/ritonavir plus interferon ß-1a | 0 | - | - | - | - | |
lopinavir/ritonavir, ribavirin and interferon beta-1b | 0 | - | - | - | - | |
meplazumab | 0 | - | - | - | - | |
nitazoxanide | 0 | - | - | - | - | |
oseltamivir | 0 | - | - | - | - | |
oseltamivir plus chloroquin | 0 | - | - | - | - | |
ribavirin | 0 | - | - | - | - | |
ritonavir | 0 | - | - | - | - | |
sofosbuvir and daclatasvir | 0 | - | - | - | - | |
tenofovir/emtricitabine | 0 | - | - | - | - | |
tenofovir/emtricitabine plus hydroxychloroquine | 0 | - | - | - | - | |
tranexamic acid | 0 | - | - | - | - | |
triazavirin | 0 | - | - | - | - | |